The following is a summary of the DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript:
Financial Performance:
DiaMedica reported total combined cash and investments of $46.5 million as of Q1 2024, and working capital of $44.9 million.
Net cash used in operating activities for the quarter was $6.7 million.
There was an increase in research and development expenses to $3.7 million, along with general and administrative expenses of $2.1 million.
Business Progress:
DiaMedica is increasing its clinical trial operations with the addition of 3 experienced personnel and continues its patient enrollment at a healthy pace.
Successful treatment of over 1 million patients with Kailikang in China in 2023 reaffirms its potential.
The company expects a significant number of site activations for its trials in Q3 2024, with the interim analysis set for Q1 2025.
DiaMedica is in the process of legally appealing a recent judgement against them concerning PRA.
More details: DiaMedica Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.